Centraal slaap apneu Central Sleep apnea Central sleep apnea syndrome
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Stable heart failure No change in medication for four weeks No evidence of fluid retention at the time of the study Only standard medical treatment, defined as an ACE inhibitor in combination with diuretics to control pulmonary or pedal edema. Digoxin and beta blockers are not considered to be standard treatment for heart failure Heart failure defined as: EF
Exclusion criteria
Exclusion criteria: Patients with known obstructive sleep apnea Patients with known pulmonary disorder Patients with known stroke Patients have a life-expectancy of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint will be four percentages (the percentage of *total* who have both a positive PG and >=15 dips/hour, the percentage of *total* who have a positive PG and = 15 dips/hour, the percentage of *total* who have a negative PG and | — |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of dectected CSA in the study population The sensitivity and specificity of pulse oximetry to detect CSAS by saturation dips > 15/h. Differences in mean dips per hour in all 26 patients for three consecutive nights The differences in mean dips per hour between the Masimo iSpO2 smart device and the oximeter which is part of the PG The percentage of detected sleep apnea by the Snore Detector Pro app, the Apnea app and the ZZZx app | — |
Countries
Netherlands
Outcome results
None listed